About

About Median Technologies Median Technologies is pioneering next-generation software as a medical device and imaging services, leveraging advanced AI to improve the precision of cancer early diagnosis and treatment. Our offerings feature iCRO, providing central imaging services and AI based image analysis for oncology trials, and eyonis®, an AI/ML-powered suite of Software as a Medical Device (SaMD). We empower biopharma companies and clinicians to accelerate the development of innovative therapies and elevate patient care. Headquartered in France with operations in the U.S. and China, Median Technologies is listed on Euronext Growth. A pioneer in applying artificial intelligence technologies to medical imaging, Median Technologies develops and markets eyonis® — a suite of AI-powered Software as a Medical Device for the early diagnosis of solid tumor cancers. The first device of the eyonis® portfolio, eyonis® LCS, is designed for lung cancer screening procedures. eyonis® LCS is currently under review for FDA 510(k) clearance in the U.S. and CE marking in Europe. In addition to its Software as a Medical Device business, Median also provides central imaging services and AI-based image analysis for oncology clinical trials in the biopharmaceutical industry through its iCRO business.